

Supplementary material

Figure S1. Cumulative incidence of aGVHD and death/relapse without aGVHD.




Figure S2. Cumulative incidence of cGVHD and death/relapse without cGVHD.




Figure S3. Cumulative incidence of NRM and RI.




Figure S4. Overall Survival for the whole cohort.





Figure S5. Cumulative incidence for CMV reactivation, stratified by letermovir prophylaxis.



CMV CI %	1 mo	3 mo	6 mo	12 mo	24 mo	36 mo
No letermovir 29 events	4.9%	20.7%	21.5%	22.3%	24.2%	24.2%
Letermovir 4 events	0	3.3%	10%	10%	18.9%	18.9%

Table S1. Cumulative incidence for NRM (at 1 year) and RI (at 2 years), overall and stratified by the main risk factors.

Characteristics	NRM at 1 yr	p-value*	RI at 2 yrs	p-value*
Overall cumulative incidence	18.2%	-	21.0%	-
<i>Age at transplant</i>				
<40 yrs	6.7%	<0.001	27.2%	0.116
40-60 yrs	14.8%		22.8%	
>60 yrs	35.1%		12.3%	
<i>Gender</i>				
Male	19.0%	0.570	24.0%	0.447
Female	17.2%		17.4%	
<i>Underlying disease</i>				
AML/ALL	17.5%	0.489	22.9%	0.501
other	18.6%		20.0%	
<i>HCT-CI</i>				
0-2	6.7%	0.007	14.5%	0.021
≥3	25.5%		27.6%	
<i>Cytogenetics</i>				
Low risk	15.1%	0.996	9.6%	0.005
Interm/High	16.7%		27.3%	
<i>Disease status at transplant</i>				
CR1	16.3%	0.949	17.4%	0.239
other	16.2%		26.0%	
<i>CMV Donor status</i>				
negative	19.5%	0.444	19.6%	0.292
positive	14.8%		23.6%	
<i>CMV Recipient status</i>				
negative	12.0%	0.042	21.4%	0.953
positive	20.8%		19.6%	
<i>Stem cell source</i>				
PBSC	38.5%	0.194	21.3%	0.829
BM	17.0%		15.4%	
<i>Number of Ly at ATG administration,</i>				
under median	19.9%	0.522	22.9%	0.998
over median	15.9%		19.6%	
<i>Number of CD34+ cells infused</i>				
under median	14.3%	0.171	19.8%	0.611
over median	20.4%		22.5%	
<i>Number of CD3+ cells infused</i>				
under median	15.8%	0.800	21.8%	0.669
over median	15.0%		19.5%	
<i>Duration of neutropenia,</i>				
		0.057		0.997

under median	9.0%		20.8%	
over median	16.8%		22.0%	
<i>Conditioning regimen</i>				
MAC	15.6%	0.012	21.3%	0.674
RIC	34.6%		18.9%	
<i>Recipient-donor HLA</i>				
<i>matched alleles</i>				
10/10 & 9/10	17.3%	0.683	22.7%	0.131
≤8/10	19.6%		15.2%	
<i>Year of transplant</i>				
2008-2012	31.9%		23.4%	
2013-2017	15.3%	0.031	21.5%	0.595
2018-2021	14.0%		18.7%	
<i>Acute GvHD</i>				
0-I	17.6%	0.236	25.0%	0.021
II-IV	19.5%		13.1%	
<i>Chronic GvHD</i>				
absent/mild	22.4%	0.136	27.0%	<0.001
moderate/severe	7.6%		6.2%	

* Comparisons calculated using Gray-test.

Table S2. Univariate and multivariate Cox proportional hazard models for Overall Survival after allogeneic HSCT

	Univariate models		Multivariate model	
	HR (95% CI)	P-value	HR (95%CI)	p-value
Age	1.30 (0.73-	0.080	1.30 (0.73-	0.127
(40-60 vs. <40 years)	2.31)	0.369	2.31)	0.157
(>60 vs. <40 years)	1.93 (1.04-	0.038	1.93 (1.04-	0.976
	3.59)		3.59)	
Gender (male vs. female)	1.30 (0.87-	0.201	-	-
	1.95)			
Underlying disease (AML/ALL vs. other)	1.06 (0.69-	0.795	-	-
	1.62)			
HCT-CI (≥ 3 vs. 0-2)	3.11 (1.86-	<0.001	3.09 (1.70-	<0.001
	5.21)		5.63)	
Cytogenetics (interm/high vs. low risk)	1.80 (1.02-	0.044	1.46 (0.77-	0.248
	3.20)		2.79)	
Disease status at transplant (other vs. CR1)*	1.27 (0.70-	0.434	-	-
	2.30)			
HLA (mismatched vs. matched)	0.84 (0.50-	0.493	-	-
	1.40)			
CMV donor status (positive vs. negative)	1.07 (0.71-	0.750	-	-
	1.61)			
CMV recipient status (positive vs. negative)	1.69 (1.04-	0.035	1.00 (0.45-	0.994
	2.76)		2.25)	
Year of transplant (2013-2017 vs. 2008-2012)	0.51 (0.32-	0.007	2.10 (0.50-	0.288
	0.82)	0.005	8.79)	0.309
(2018-2021 vs. 2008-2012)	0.49 (0.29-	0.007	1.32 (0.30-	0.712
	0.82)		5.71)	
Graft source (PBSC vs. BM)	0.76 (0.35-	0.487	-	-
	1.64)			
Number of Ly at ATG administration (over vs. under median), $10^6/l$	0.86 (0.58-	0.470	-	-
	1.29)			
Number of CD34+ cells infused (over vs. under median), $10^6/kg$	1.34 (0.89-	0.169	-	-
	2.02)			
Number of CD3+ cells infused (over vs. under median), $10^8/kg$	0.89 (0.57-	0.892	-	-
	1.40)			
Duration of neutropenia (over vs. under median), days	1.36 (0.88-	0.172	-	-
	2.11)			

Conditioning (RIC vs. MAC)	1.71 (1.02-2.90)	0.044	1.15 (0.48-2.76)	0.749
Acute GvHD II-IV (yes vs. no) *	0.66 (0.39-1.13)	0.130	-	-
Chronic GvHD moderate-severe (yes vs. no) *	0.19 (0.09-0.40)	<0.001	0.12 (0.04-0.43)	0.001
